Heart Failure – Current Treatment – Detailed, Expanded Analysis – Patient Profiler – US

Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established and heavily genericized. Real-world data (RWD) reveals that oral loop diuretics, beta blockers, and ACE inhibitors are the cornerstones of CHF therapy. However, Entresto, the most recent addition to the CHF armamentarium, continues to experience growing patient share. Here we explore drug-prescribing patterns in CHF and reveal the main characteristics of patients receiving the key CHF agents.

Questions answered:

  •  What is the patient share in CHF for Entresto, Corlanor, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), diuretics, nitrates, spironolactone, eplerenone, and other key drug classes?
  • What are the demographic characteristics and clinical profiles of CHF patients prescribed Entresto, Corlanor, and the key drug classes?
  • What are the key risk factors, comorbidities, and coprescribed therapies by patient segment for CHF?
  • How do patient cohorts in CHF compare in care utilization and outcomes (physician visits and other healthcare encounters)?
  • What kind of insurance and provider do CHF patients have?
  • What are the reimbursed and out-of-pocket costs for CHF therapies?

Product description:

Patient Profiler provides disease-specific, patient-level analysis of the key demographic, clinical, and cost-based metrics underlying brand use, all sourced with DRG’s comprehensive RWD repository.

Markets covered: United States

Key drugs covered: Entresto, Corlanor, BiDil, Coreg CR, Toprol XL, Lasix, beta blockers, ACE inhibitors, ARBs, diuretics, nitrates, spironolactone, eplerenone

Table of contents

  • Heart Failure - Current Treatment - Detailed, Expanded Analysis - Patient Profiler - US
    • Patient Profiler u2013 Chronic Heart Failure u2013 2018 u2013 US
    • Please Note:

launch Related Market Assessment Reports